Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophages targeting Enterobacter
- Development stage
- Preclinical
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Bacteriophages targeting *Enterobacter* are a class of lytic bacterial viruses being investigated as a potential phage therapy to combat multidrug-resistant and carbapenem-resistant *Enterobacter* infections. These phages specifically infect and lyse *Enterobacter* species, such as *Enterobacter cloacae* and *Enterobacter xiangfangensis*, which are common pathogens in hospital-acquired infections (including bacteremia, lower respiratory tract infections, and urinary tract infections). By binding to specific bacterial cell surface receptors, these bacteriophages inject their genetic material, replicate within the host, and ultimately cause bacterial lysis, offering a highly specific, self-replicating, and self-limiting alternative or adjunct to conventional antibiotic therapy.
- Other names
- Enterobacter bacteriophagesEnterobacter phagesbacteriophages against Enterobacterlytic bacteriophages targeting Enterobacter
02
Targets
FhuA (Ferrichrome outer membrane transporter)TonB (TonB energy transducer protein)
Beyond the preview
Go deeper on bacteriophages targeting Enterobacter.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophages targeting Enterobacter.